USSTOCK.TODAY
Regular Market
Log in Sign up

Recursion Pharmaceuticals Beats Revenue Estimates and Secures Funding Through 2029

Earnings Whispers · ·by G4L

RXRX
RXRX Recursion Pharmaceuticals Inc
$3.81 +8.10%
View chart & analysis →
  1. 1Recursion Pharmaceuticals recorded $18.55 million in revenue for the third quarter.
  2. 2Recursion Pharmaceuticals achieved an earnings surprise rate of 8.3% in the third quarter.
  3. 3Recursion Pharmaceuticals aims to conduct registered clinical trials in the second half of 2027.

So what's the key point?

Recursion Pharmaceuticals' third-quarter revenue was 8.3 percent higher than what experts expected. The company plans to proceed with clinical trials through the second half of 2027.

Source Earnings Whispers · View original ↗

Related 3-line summaries

Recursion Pharmaceuticals Extends Financial Runway to 2029 and Shifts Operational Focus The Motley Fool +1 · 6d agoFTC and 7 States Seek Contempt Charges Against Martin Shkreli, Banned from Pharmaceutical Industry Investing.com +2 · Oct 13Recursion Pharmaceuticals posts Q2 loss of $131 million, missing estimates Associated Press +1 · Aug 5
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news